Investment Rating - The report maintains an "Outperform" rating for the company [4][9]. Core Insights - The company has partnered with Dassault Systems to launch "inSuite by DELMIAWorks," an integrated industrial software aimed at accelerating smart manufacturing upgrades [10][12]. - The report projects the company's net profit attributable to shareholders for 2025, 2026, and 2027 to be 553 million, 703 million, and 892 million RMB, respectively, with EPS of 0.48, 0.61, and 0.77 RMB [4][9]. - A target price of 13.03 HKD is assigned based on a 2025 forward PE of 25x [4][9]. Financial Summary - The total revenue is projected to be 8,294 million RMB in 2023, with a growth rate of 19.1%, followed by a slight decline of 1.1% in 2024, and then growth rates of 9.3%, 10.1%, and 11.5% in the subsequent years [3][7]. - Gross profit is expected to increase from 1,918 million RMB in 2023 to 3,300 million RMB by 2027 [3][7]. - The report indicates a significant increase in net profit, with a forecasted growth of 69.9% in 2024, followed by 90.8% in 2025, and steady growth in the following years [3][7]. Business Strategy and Market Potential - The inSuite by DELMIAWorks software integrates various manufacturing processes, addressing challenges such as data silos and enhancing business collaboration [11][12]. - The report highlights the potential for integrated industrial software, supported by government policies aimed at digital transformation in the machinery industry, with a target of 50% of companies achieving a smart manufacturing maturity level of two or above by 2027 [12].

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][19] Core Views - The company is a leader in overseas cement production, with a strong presence in sub-Saharan Africa, and has initiated its overseas strategy since 2020 [2][11] - The company is expected to achieve significant growth in net profit from 2025 to 2027, with projected figures of 1.143 billion, 1.422 billion, and 2.015 billion RMB respectively [19] - The report highlights the company's strategic decision to divest from domestic assets in Xinjiang to alleviate debt pressure and support overseas expansion [11][19] Financial Summary - Total revenue is projected to grow from 9.024 billion RMB in 2023 to 14.146 billion RMB in 2027, with a CAGR of approximately 17% [4] - Gross profit is expected to increase from 2.460 billion RMB in 2023 to 5.227 billion RMB in 2027 [4] - Net profit is forecasted to recover from a significant drop in 2023 to 2.015 billion RMB by 2027, reflecting a strong recovery trajectory [4] Market Position - The company holds the largest market share in Shaanxi province, with a production capacity of 21.7 million tons, leading the local market [21][24] - The company has established a diversified overseas presence in countries such as Mozambique, Congo, Ethiopia, and Uzbekistan, with plans for further expansion [11][66] Overseas Expansion - The company has seen rapid growth in overseas sales, reaching 403 million tons in 2024 and expected to exceed 880 million tons by 2025 [69] - The average selling price of cement in overseas markets is significantly higher than in China, contributing to higher profit margins [72] - The report emphasizes the strong demand for cement in sub-Saharan Africa, driven by population growth and economic development [45][51]

Investment Rating - The report maintains an "Outperform" rating for J&T Express [2][6] Core Insights - J&T Express continues to experience high growth in Southeast Asia, with a significant increase in package volume driven by e-commerce penetration and company competitiveness [6][7] - The company has expanded its new market operations, achieving a 47.9% year-on-year growth in package volume for Q3 2025, supported by investments and partnerships with e-commerce platforms [6][7] - The report anticipates a recovery in profit margins due to rising delivery prices in the express delivery industry, following a trend of price increases since August [6][7] Financial Data and Profit Forecast - Revenue projections for J&T Express are as follows: - 2023: $8,849 million - 2024: $10,259 million - 2025E: $12,719 million - 2026E: $16,015 million - 2027E: $20,449 million - Year-on-year growth rates for revenue are projected at 21.77% for 2023, 15.93% for 2024, and 23.97% for 2025E [3][7] - Adjusted net profit forecasts are: - 2025E: $368 million - 2026E: $592 million - 2027E: $853 million - Corresponding year-on-year growth rates for adjusted net profit are 83.91% for 2025E, 60.77% for 2026E, and 43.94% for 2027E [3][7] Market Performance - As of October 14, 2025, J&T Express's closing price is HKD 9.61, with a market capitalization of HKD 862.75 billion [4][6] - The company has a market share of 32.8% in Southeast Asia, reflecting a 5.4 percentage point increase year-on-year [6][7]

Investment Rating - The report initiates coverage with an "Outperform" rating for the company [3]. Core Insights - The company is a leader in congenital heart disease interventional medical devices in China, with a strong existing product pipeline and significant growth potential in both traditional biodegradable products and new heart valve products [1][2]. - The company achieved a revenue of 330 million RMB in H1 2025, representing a year-on-year growth of 32.4%, and a net profit of 182 million RMB, up 29.8% [3][9]. Financial Summary - Projected total revenue for 2024A is 472 million RMB, with a growth rate of 45%, and expected to reach 1.231 billion RMB by 2027E, with a growth rate of 28% [3]. - The net profit is forecasted to grow from 246 million RMB in 2024A to 503 million RMB in 2027E, with a CAGR of 26% [3]. - The company’s PE ratio is projected to decrease from 24.54 in 2024A to 14.07 in 2027E, indicating improving valuation metrics over time [3]. Business Segments - The company has a robust product portfolio with 30 marketed products and 28 in various stages of development, focusing on congenital heart disease, stroke, and valve disease [8][15]. - The biodegradable occluder products are gaining popularity due to their clinical advantages over metal devices, reducing long-term complications [3][12]. - The heart valve segment is expected to become a significant growth driver, with the market for transcatheter aortic valve replacement (TAVR) projected to grow at a CAGR of 52% from 2021 to 2025 [3][4]. Market Potential - The congenital heart disease occluder market in China is expected to grow at a CAGR of 11.5%, reaching 659 million RMB by 2025 [25][30]. - The overall interventional medical device market for structural heart diseases is projected to reach 10.4 billion RMB in China by 2025, with a CAGR of 51% from 2021 to 2025 [22][24]. Competitive Position - The company holds a 38% market share in the congenital heart disease occluder market in China, indicating a strong competitive position against both domestic and international manufacturers [30][34]. - The company is well-positioned to capitalize on the growing demand for minimally invasive procedures, which are increasingly replacing traditional surgical methods [18][19].

Investment Rating - The investment rating for JD Group is maintained at "Outperform the Market" [1][4][10] Core Views - JD Group is expected to report a strong revenue performance for Q3 2025, with an estimated revenue of CNY 293.9 billion, representing a year-on-year increase of 13%. This growth is primarily driven by government subsidies boosting retail revenue growth [3][5] - The Non-GAAP net profit margin is projected to decline by 4 percentage points year-on-year to 1.4% for Q3 2025, influenced by ongoing losses in the new food delivery business, although there are signs of improvement in user experience (UE) [3][6] - The company is adjusting its revenue forecasts for 2025-2027 to CNY 1,334.8 billion, CNY 1,419.7 billion, and CNY 1,488.2 billion respectively, with a slight increase in net profit forecasts for the same period [4][10] Revenue Performance - Q3 2025 revenue is expected to be CNY 293.9 billion, up 13% year-on-year, with JD Retail revenue growth anticipated at 11%. The growth in the electronics category is expected to be in the high single digits, while daily necessities are projected to grow in double digits [3][5] - The food delivery business is expected to see a significant revenue increase of 230% in Q3 2025, benefiting from seasonal demand [3][5] Operational Insights - The estimated GMV growth for JD in Q3 2025 is around 15%, with market share continuing to recover, largely driven by the "old-for-new" subsidy program in the electronics category [3][5] - Active purchasing users and purchase frequency in e-commerce are showing strong growth, with 40% of new food delivery users converting to main site users by July [3][5] Profitability Analysis - The Non-GAAP net profit margin is expected to be 1.4% for Q3 2025, down 3.6 percentage points year-on-year. However, JD Retail's operating profit margin is projected to improve by 0.3 percentage points due to enhanced supply chain efficiency and increased commission and advertising revenue [6][10] - The losses from the new food delivery business are impacting overall profitability, but improvements in delivery efficiency and targeted subsidies are helping to reduce these losses [6]

Investment Rating - The investment rating for the company is "Outperform the Market" [2][4][9] Core Views - The company reported a retail performance for Q3 2025 with approximately 10% growth in both the main brand's offline retail and children's clothing, and around 20% growth in e-commerce [3][4] - The company continues to innovate products to meet diverse consumer needs and has expanded its super stores to 93 locations, maintaining stable inventory levels and slightly increasing discounts [4][6][9] - The company is expected to maintain its profit forecasts, with projected net profits of 1.25 billion, 1.35 billion, and 1.48 billion yuan for 2025-2027, reflecting year-on-year growth of 8.5%, 8.7%, and 9.4% respectively [4][10][11] Summary by Sections Retail Performance - In Q3 2025, the adult apparel offline sales grew by approximately 10%, children's apparel also grew by about 10%, and e-commerce sales increased by around 20%, with growth rates remaining stable compared to previous quarters [4][5][6] Product Innovation - The company has launched new products across various categories, including running shoes with enhanced waterproof technology, basketball shoes with advanced design features, and children's shoes tailored for young athletes [6][7] Channel Expansion - The company has expanded its super stores to 93, with 44 new stores opened in Q3. These stores offer a comprehensive range of products and a one-stop shopping experience [6][7] Financial Projections - The company forecasts revenue growth of 21% in 2023, 19.6% in 2024, and 11% in 2025, with net profit growth of 28.7% in 2023 and 19.5% in 2024 [10][14]

Investment Rating - The report initiates coverage on Aux Electric with a "Buy" rating and a target price of HKD 17.67, based on an 8x PE for 2025 [5][4]. Core Insights - Aux Electric is the fifth largest air conditioning provider globally and the fourth largest in China, with a market share of 7.1% globally and 7.3% in China for 2024 [1][18]. - The company has a robust presence in over 150 countries, focusing on both domestic and international markets through a dual strategy of ODM and OBM [1][18]. - The report highlights Aux's historical adaptability and strategic positioning, capturing market opportunities across different eras, from cost-effective products in the early 2000s to leveraging e-commerce in the 2010s and expanding globally in the 2020s [1][21]. Summary by Sections Company Overview - Aux Electric entered the air conditioning industry in 1994 and has since developed a multi-brand strategy, including the main brand Aux and sub-brands like ShinFlow, HuaSuan, and Aufit, to cater to various market segments [23][1]. - The company has maintained a strong growth trajectory, with a projected revenue of RMB 29.8 billion in 2024 and a CAGR of 30% in air conditioning sales from 2023 to 2024 [23][18]. Market Outlook - The global air conditioning market is expected to grow from RMB 1.31 trillion in 2024 to RMB 1.53 trillion in 2028, with a CAGR of 4.0% [2]. - Aux is actively expanding in emerging markets, particularly in the Middle East and Southeast Asia, with significant contributions from both ODM and OBM business models [2][18]. Financial Projections - The report forecasts Aux's net profit attributable to shareholders to be RMB 3.167 billion, RMB 3.661 billion, and RMB 4.073 billion for 2025, 2026, and 2027, respectively, with corresponding EPS of RMB 1.99, RMB 2.31, and RMB 2.56 [4][12]. - Revenue from overseas sales is expected to reach RMB 188.9 billion, RMB 234.6 billion, and RMB 281.8 billion from 2025 to 2027, accounting for 54.3%, 58.5%, and 62.6% of total revenue [2][4]. Competitive Positioning - Aux Electric's manufacturing efficiency is highlighted, with a capacity utilization rate of 91.3% compared to the industry average of 74.4% in 2024, which enhances its bargaining power [3][22]. - The company has diversified its customer base, reducing dependency on any single client, with the largest customer accounting for only 6.3% of revenue in Q1 2025 [22][3].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company has demonstrated strong sales performance, achieving a signed sales amount of 98.0 billion yuan in September 2025, with a total of 806.9 billion yuan for the first nine months of 2025, reflecting a year-on-year increase of 27.3% [1][3] - The brand value of the company has been a significant driver of its development, with a brand value of 742 billion yuan in 2025, marking an increase of nearly 8 billion yuan from the previous year [2] - The company has seen a notable decrease in expense ratios, with management and sales expense ratios dropping to 4.8% and 3.3% respectively for the first half of 2025, indicating improved operational efficiency [4] Summary by Sections Sales Performance - The company reported monthly signed sales amounts of 84.6 billion yuan, 90.8 billion yuan, and 98.0 billion yuan for July, August, and September 2025 respectively, with year-on-year growth rates of 49.5%, 46.5%, and 39.9% [3] - For the third quarter of 2025, the signed sales amount reached 273.4 billion yuan, up from 188.6 billion yuan in the same period of 2024, with a signed sales area of 128.1 million square meters [3] Financial Forecast and Valuation - The profit forecast for the company has been revised upwards for 2025-2027, with expected net profits of 1.25 billion yuan, 1.43 billion yuan, and 1.58 billion yuan respectively [4] - The current stock price corresponds to a price-to-earnings (PE) ratio of 13.7, 12.0, and 10.8 for the years 2025-2027 [4]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company has shown rapid revenue growth, with a 21.8% year-on-year increase in total revenue for the first three quarters of 2025, amounting to 10.21 billion yuan [8] - The HNB (Heated Not Burned) products are gradually being promoted, with positive feedback from customers and plans for expansion into new markets [8] - The company is expected to benefit from stricter regulations in the electronic vaporization market, leading to a recovery in its business [8] Financial Summary - Total revenue projections for 2023A, 2024A, 2025E, 2026E, and 2027E are 11,168 million yuan, 11,799 million yuan, 13,722 million yuan, 16,166 million yuan, and 18,395 million yuan respectively, with year-on-year growth rates of -8.04%, 5.64%, 16.30%, 17.81%, and 13.79% [1] - The net profit attributable to the parent company for the same years is projected to be 1,645 million yuan, 1,303 million yuan, 1,331 million yuan, 2,219 million yuan, and 2,893 million yuan, with year-on-year growth rates of -34.47%, -20.78%, 2.11%, 66.75%, and 30.37% [1] - The latest diluted EPS (Earnings Per Share) is forecasted to be 0.27 yuan, 0.21 yuan, 0.21 yuan, 0.36 yuan, and 0.47 yuan for the years 2023A to 2027E [1] Market Data - The closing price of the company's stock is 15.77 HKD, with a market capitalization of approximately 89.18 billion HKD [5] - The price-to-book ratio is 3.97 [5] - The company has a total share capital of 6,193.04 million shares [6]

Investment Rating - The investment rating for the company is "Buy" with a target price set for the next six months [6][14]. Core Insights - The company achieved a record high revenue of 41.97 billion yuan in Q3 2025, marking a 27.5% increase quarter-on-quarter and a 27.2% increase year-on-year. However, net profit for the same quarter was 3.17 billion yuan, reflecting a 16.4% year-on-year decline [1][2]. - The HNB (Heated Not Burned) business saw a significant increase in shipment volumes, contributing to the overall revenue growth. The company is also expanding its self-owned brand business and enhancing localized marketing efforts [2][5]. - The medical aerosol business has made a breakthrough with the submission of an ANDA application for Breo® Ellipta®, which, if approved, could provide a 180-day market exclusivity in the U.S. This product is expected to generate significant sales in the future [4][5]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenues of 102.10 billion yuan, a year-on-year increase of 21.8%. Adjusted net profit was 11.82 billion yuan, a slight increase of 0.1% year-on-year [1]. - In Q3 2025, the company achieved revenues of 41.97 billion yuan, with an adjusted net profit of 4.44 billion yuan, reflecting a 4.0% year-on-year increase [1][2]. Business Growth - The company’s HNB and electronic vaporization businesses both experienced growth, with strategic clients successfully launching new products in major global markets [2]. - The GloHilo product line is being introduced in Italy, Poland, and Serbia, aiming to reach 50 million adult consumers of smoke-free products by 2030 [3]. Future Outlook - The company is expected to see significant contributions from the HNB business starting in 2026, with adjusted net profit forecasts for 2025-2027 revised to 13.92 billion, 20.23 billion, and 27.59 billion yuan respectively [5].